Global Drugs for Vulvovaginal Candidiasis Market Research Report 2023(Status and Outlook)

Global Drugs for Vulvovaginal Candidiasis Market Research Report 2023(Status and Outlook)



Report Overview

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.

The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.

The Asia-Pacific region is the world's largest market, with a market share of about 45%, followed by North America with nearly 20%

The Global Drugs for Vulvovaginal Candidiasis Market Size was estimated at USD 804.50 million in 2022 and is projected to reach USD 892.87 million by 2029, exhibiting a CAGR of 1.50% during the forecast period.

Bosson Research’s latest report provides a deep insight into the global Drugs for Vulvovaginal Candidiasis market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Drugs for Vulvovaginal Candidiasis Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Drugs for Vulvovaginal Candidiasis market in any manner.

Global Drugs for Vulvovaginal Candidiasis Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Bayer

Perrigo

J & J

Pfizer

Bristol-Myers Squibb

Effik

Teva

Sanofi

Cisen Pharmaceutical

Kingyork Group

Market Segmentation (by Type)

Cream

Pessary

Other

Market Segmentation (by Application)

Hospital

Family

Other

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Drugs for Vulvovaginal Candidiasis Market

Overview of the regional outlook of the Drugs for Vulvovaginal Candidiasis Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Drugs for Vulvovaginal Candidiasis
1.2 Key Market Segments
1.2.1 Drugs for Vulvovaginal Candidiasis Segment by Type
1.2.2 Drugs for Vulvovaginal Candidiasis Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Drugs for Vulvovaginal Candidiasis Market Overview
2.1 Global Market Overview
2.1.1 Global Drugs for Vulvovaginal Candidiasis Market Size (M USD) Estimates and Forecasts (2018-2029)
2.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Estimates and Forecasts (2018-2029)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Drugs for Vulvovaginal Candidiasis Market Competitive Landscape
3.1 Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2018-2023)
3.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturers (2018-2023)
3.3 Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Drugs for Vulvovaginal Candidiasis Average Price by Manufacturers (2018-2023)
3.5 Manufacturers Drugs for Vulvovaginal Candidiasis Sales Sites, Area Served, Product Type
3.6 Drugs for Vulvovaginal Candidiasis Market Competitive Situation and Trends
3.6.1 Drugs for Vulvovaginal Candidiasis Market Concentration Rate
3.6.2 Global 5 and 10 Largest Drugs for Vulvovaginal Candidiasis Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Drugs for Vulvovaginal Candidiasis Industry Chain Analysis
4.1 Drugs for Vulvovaginal Candidiasis Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Drugs for Vulvovaginal Candidiasis Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Drugs for Vulvovaginal Candidiasis Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2018-2023)
6.3 Global Drugs for Vulvovaginal Candidiasis Market Size Market Share by Type (2018-2023)
6.4 Global Drugs for Vulvovaginal Candidiasis Price by Type (2018-2023)
7 Drugs for Vulvovaginal Candidiasis Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Drugs for Vulvovaginal Candidiasis Market Sales by Application (2018-2023)
7.3 Global Drugs for Vulvovaginal Candidiasis Market Size (M USD) by Application (2018-2023)
7.4 Global Drugs for Vulvovaginal Candidiasis Sales Growth Rate by Application (2018-2023)
8 Drugs for Vulvovaginal Candidiasis Market Segmentation by Region
8.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region
8.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region
8.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region
8.2 North America
8.2.1 North America Drugs for Vulvovaginal Candidiasis Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Drugs for Vulvovaginal Candidiasis Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Bayer
9.1.1 Bayer Drugs for Vulvovaginal Candidiasis Basic Information
9.1.2 Bayer Drugs for Vulvovaginal Candidiasis Product Overview
9.1.3 Bayer Drugs for Vulvovaginal Candidiasis Product Market Performance
9.1.4 Bayer Business Overview
9.1.5 Bayer Drugs for Vulvovaginal Candidiasis SWOT Analysis
9.1.6 Bayer Recent Developments
9.2 Perrigo
9.2.1 Perrigo Drugs for Vulvovaginal Candidiasis Basic Information
9.2.2 Perrigo Drugs for Vulvovaginal Candidiasis Product Overview
9.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Product Market Performance
9.2.4 Perrigo Business Overview
9.2.5 Perrigo Drugs for Vulvovaginal Candidiasis SWOT Analysis
9.2.6 Perrigo Recent Developments
9.3 J andamp; J
9.3.1 J andamp; J Drugs for Vulvovaginal Candidiasis Basic Information
9.3.2 J andamp; J Drugs for Vulvovaginal Candidiasis Product Overview
9.3.3 J andamp; J Drugs for Vulvovaginal Candidiasis Product Market Performance
9.3.4 J andamp; J Business Overview
9.3.5 J andamp; J Drugs for Vulvovaginal Candidiasis SWOT Analysis
9.3.6 J andamp; J Recent Developments
9.4 Pfizer
9.4.1 Pfizer Drugs for Vulvovaginal Candidiasis Basic Information
9.4.2 Pfizer Drugs for Vulvovaginal Candidiasis Product Overview
9.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Product Market Performance
9.4.4 Pfizer Business Overview
9.4.5 Pfizer Drugs for Vulvovaginal Candidiasis SWOT Analysis
9.4.6 Pfizer Recent Developments
9.5 Bristol-Myers Squibb
9.5.1 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Basic Information
9.5.2 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Overview
9.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Market Performance
9.5.4 Bristol-Myers Squibb Business Overview
9.5.5 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis SWOT Analysis
9.5.6 Bristol-Myers Squibb Recent Developments
9.6 Effik
9.6.1 Effik Drugs for Vulvovaginal Candidiasis Basic Information
9.6.2 Effik Drugs for Vulvovaginal Candidiasis Product Overview
9.6.3 Effik Drugs for Vulvovaginal Candidiasis Product Market Performance
9.6.4 Effik Business Overview
9.6.5 Effik Recent Developments
9.7 Teva
9.7.1 Teva Drugs for Vulvovaginal Candidiasis Basic Information
9.7.2 Teva Drugs for Vulvovaginal Candidiasis Product Overview
9.7.3 Teva Drugs for Vulvovaginal Candidiasis Product Market Performance
9.7.4 Teva Business Overview
9.7.5 Teva Recent Developments
9.8 Sanofi
9.8.1 Sanofi Drugs for Vulvovaginal Candidiasis Basic Information
9.8.2 Sanofi Drugs for Vulvovaginal Candidiasis Product Overview
9.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Product Market Performance
9.8.4 Sanofi Business Overview
9.8.5 Sanofi Recent Developments
9.9 Cisen Pharmaceutical
9.9.1 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Basic Information
9.9.2 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Overview
9.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Market Performance
9.9.4 Cisen Pharmaceutical Business Overview
9.9.5 Cisen Pharmaceutical Recent Developments
9.10 Kingyork Group
9.10.1 Kingyork Group Drugs for Vulvovaginal Candidiasis Basic Information
9.10.2 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Overview
9.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Market Performance
9.10.4 Kingyork Group Business Overview
9.10.5 Kingyork Group Recent Developments
10 Drugs for Vulvovaginal Candidiasis Market Forecast by Region
10.1 Global Drugs for Vulvovaginal Candidiasis Market Size Forecast
10.2 Global Drugs for Vulvovaginal Candidiasis Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Drugs for Vulvovaginal Candidiasis Market Size Forecast by Country
10.2.3 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Size Forecast by Region
10.2.4 South America Drugs for Vulvovaginal Candidiasis Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Drugs for Vulvovaginal Candidiasis by Country
11 Forecast Market by Type and by Application (2024-2029)
11.1 Global Drugs for Vulvovaginal Candidiasis Market Forecast by Type (2024-2029)
11.1.1 Global Forecasted Sales of Drugs for Vulvovaginal Candidiasis by Type (2024-2029)
11.1.2 Global Drugs for Vulvovaginal Candidiasis Market Size Forecast by Type (2024-2029)
11.1.3 Global Forecasted Price of Drugs for Vulvovaginal Candidiasis by Type (2024-2029)
11.2 Global Drugs for Vulvovaginal Candidiasis Market Forecast by Application (2024-2029)
11.2.1 Global Drugs for Vulvovaginal Candidiasis Sales (K MT) Forecast by Application
11.2.2 Global Drugs for Vulvovaginal Candidiasis Market Size (M USD) Forecast by Application (2024-2029)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings